21st Century Cures 2.0.
H.R.5376: Build Back Better Act as it relates to H.R.3: Elijah E. Cummings Lower Drug Costs Now Act, H.R.19. Lower Costs, More Cures Act of 2021 and Orphan Drug Tax Credit.
Duration: May 1, 2010
to
December 31, 2021
General Issues: Health Issues , Medicare/Medicaid , Taxation/Internal Revenue Code , Trade (Domestic & Foreign) , Copyright/Patent/Trademark
Spending: about $2,530,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2010: House of Representatives, U.S. Senate, Office of Management & Budget (OMB), U.S. Trade Representative (USTR), U.S. Senate,, House of Representatives,, Health & Human Services - Dept of (HHS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Darren Willcox Assistant for Policy, Speaker Dennis Hastert (2001-2004)
Admin. Asst, Leg. Dir, Leg Asst, Cong. Porter Goss (1995-01)
House Rules Comm. Associate, Subcom. Staff Dir., (1997-01)
Asst for Policy, Speaker Dennis Hastert
Admin Asst; Leg Dir; Leg Asst, Cong. Porter Goss
House Rules Comm Assoc, Subcomm Staff Dir.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2021
W Strategies, LLC terminated an engagement in which they represented Alexion Pharmaceuticals on Jan. 20, 2022.
Original Filing: 301331670.xml
Lobbying Issues
21st Century Cures 2.0.
H.R.5376: Build Back Better Act as it relates to H.R.3: Elijah E. Cummings Lower Drug Costs Now Act, H.R.19. Lower Costs, More Cures Act of 2021 and Orphan Drug Tax Credit.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2021
In Q3, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $60,000. The report was filed on Oct. 20, 2021.
Original Filing: 301310004.xml
Lobbying Issues
21st Century Cures 2.0.
FY 22 Budget Reconciliation as it relates to H.R.3: Elijah E. Cummings Lower Drug Costs Now Act, H.R.19: Lower Costs, More Cures Act of 2021 and the Orphan Drug Tax Credit.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2021
In Q2, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $60,000. The report was filed on July 19, 2021.
Original Filing: 301283305.xml
Lobbying Issues
Education around access issues for rare therapies in the inpatient setting.
ICD diagnosis codes for rare disease.
21st Century Cures 2.0.
H.R.3: Elijah E. Cummings Lower Drug Costs Now Act.
H.R.19: Lower Costs, More Cures Act of 2021.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2021
In Q1, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $60,000. The report was filed on April 20, 2021.
Original Filing: 301260718.xml
Lobbying Issues
Education around access issues for rare therapies in the inpatient setting.
H.R.1319 - American Rescue Plan Act of 2021.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2020
In Q4, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $60,000. The report was filed on Jan. 20, 2021.
Original Filing: 301240674.xml
Lobbying Issues
CMS IPPS rule as it relates to the NTAP program.
H.R.133: Consolidated Appropriations Act, 2021.
Administration Executive Order and Rulemaking in International Drug Pricing.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2020
In Q3, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $60,000. The report was filed on Oct. 20, 2020.
Original Filing: 301222634.xml
Lobbying Issues
CMS IPPS rule as it relates to the NTAP program.
Administration Executive Order on International Drug Pricing.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2020
In Q2, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $60,000. The report was filed on July 20, 2020.
Original Filing: 301201602.xml
Lobbying Issues
H.R.1425: Patient Protection and Affordable Care Enhancement Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
CMS IPPS rule as it relates to the NTAP program.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2020
In Q1, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $60,000. The report was filed on April 20, 2020.
Original Filing: 301176672.xml
Lobbying Issues
H.R.4712: Fairness in Orphan Drug Exclusivity Act.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2019
In Q4, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $60,000. The report was filed on Jan. 21, 2020.
Original Filing: 301128857.xml
Lobbying Issues
H.R.4378: Continuing Appropriations Act, 2020, and Health Extenders Act of 2019.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Regulatory and legislative proposals in the Administration's Rx Blueprint.
H.R.3: Lower Drug Costs Now Act of 2019.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2019
In Q3, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $60,000. The report was filed on Oct. 21, 2019.
Original Filing: 301078379.xml
Lobbying Issues
Education about the value of innovative new medicines and the Orphan Drug Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S.2543: Prescription Drug Pricing Reduction Act of 2019.
Regulatory and legislative proposals in the Administration's Rx Blueprint.
H.R.3: Lower Drug Costs Now Act of 2019.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2019
In Q2, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $60,000. The report was filed on July 22, 2019.
Original Filing: 301056762.xml
Lobbying Issues
Education about the value of innovative new medicines and the Orphan Drug Act.
S.: Lower Health Care Costs Act of 2019.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about reimbursement for orphan drug therapies in skilled nursing facilities and proposed add-on payments in inpatient hospitals.
H.R.2113: Prescription Drug STAR Act.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2019
In Q1, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $60,000. The report was filed on April 22, 2019.
Original Filing: 301035092.xml
Lobbying Issues
Education about the value of innovative new medicines and the Orphan Drug Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about reimbursement for orphan drug therapies in skilled nursing facilities and proposed add-on payments in inpatient hospitals.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2018
In Q4, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $60,000. The report was filed on Jan. 22, 2019.
Original Filing: 301015889.xml
Lobbying Issues
Education about the value of innovative new medicines and the Orphan Drug Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about reimbursement for orphan drug therapies in skilled nursing facilities and proposed add-on payments in inpatient hospitals.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2018
In Q3, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $60,000. The report was filed on Oct. 16, 2018.
Original Filing: 300985885.xml
Lobbying Issues
Education about the value of innovative new medicines and the Orphan Drug Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about reimbursement for orphan drug therapies in skilled nursing facilities and proposed add-on payments in inpatient hospitals.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2018
In Q2, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $60,000. The report was filed on July 20, 2018.
Original Filing: 300975532.xml
Lobbying Issues
Education about the value of innovative new medicines and the Orphan Drug Act.
H.R.3: Spending Cuts to Expired and Unnecessary Programs Act as it relates to CHIP funding.
Right to Try legislation.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about reimbursement for orphan drug therapies in skilled nursing facilities and proposed add-on payments in inpatient hospitals.
Medicare home Infusion benefit under Part B.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2018
W Strategies, LLC terminated an engagement in which they represented Alexion Pharmaceuticals on April 19, 2018.
Original Filing: 300951064.xml
Lobbying Issues
Education about the value of innovative new medicines and the Orphan Drug Act.
H.R.195: Making further continuing appropriations for the fiscal year ending September 30, 2018, and for other purposes, as it relates to the HEALTHY KIDS Act CHIP reauthorization.
Reauthorization of the Animal Drug User Fee Act (ADUFA).
Right to Try legislation.
H.R.4679: Ensuring Equal Access to Treatments Act of 2017.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about reimbursement for orphan drug therapies in skilled nursing facilities and proposed add-on payments in inpatient hospitals.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2018
W Strategies, LLC amended a lobbying report for representation of Alexion Pharmaceuticals in Q12018 on April 19, 2018.
Original Filing: 300951080.xml
Lobbying Issues
Education about the value of innovative new medicines and the Orphan Drug Act.
H.R.195: Making further continuing appropriations for the fiscal year ending September 30, 2018, and for other purposes, as it relates to the HEALTHY KIDS Act CHIP reauthorization.
Reauthorization of the Animal Drug User Fee Act (ADUFA).
Right to Try legislation.
H.R.4679: Ensuring Equal Access to Treatments Act of 2017.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about reimbursement for orphan drug therapies in skilled nursing facilities and proposed add-on payments in inpatient hospitals.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2018
In Q1, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $60,000. The report was filed on April 19, 2018.
Original Filing: 300950263.xml
Lobbying Issues
Education about the value of innovative new medicines and the Orphan Drug Act.
H.R.195: Making further continuing appropriations for the fiscal year ending September 30, 2018, and for other purposes, as it relates to the HEALTHY KIDS Act CHIP reauthorization.
Reauthorization of the Animal Drug User Fee Act (ADUFA).
Right to Try legislation.
H.R.4679: Ensuring Equal Access to Treatments Act of 2017.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about reimbursement for orphan drug therapies in skilled nursing facilities and proposed add-on payments in inpatient hospitals.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2017
In Q4, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $60,000. The report was filed on Jan. 19, 2018.
Original Filing: 300929325.xml
Lobbying Issues
Education about the value of innovative new medicines and the Orphan Drug Act.
H.R.3922: CHAMPIONING HEALTHY KIDS Act.
H.R.4679: Ensuring Equal Access to Treatments Act of 2017.
Education about the 340(b) program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about reimbursement for orphan drug therapies in skilled nursing facilities and proposed add-on payments in inpatient hospitals.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.1/S.1: Tax Cuts and Jobs Act, as it relates to the Orphan Drug Tax Credit.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2017
In Q3, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $60,000. The report was filed on Oct. 20, 2017.
Original Filing: 300915521.xml
Lobbying Issues
Education about the value of innovative new medicines and the Orphan Drug Act.
H.R.1231/S.456: RACE for Children Act.
H.R.2430/S.934: FDA Reauthorization Act of 2017.
Education about the 340(b)m program.
H.R.1628: American Health Care Act. Better Care Reconciliation Act and S. Better Care Reconciliation Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about reimbursement for orphan drug therapies in skilled nursing facilities and proposed add-on payments in inpatient hospitals.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2017
In Q2, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $60,000. The report was filed on July 20, 2017.
Original Filing: 300897235.xml
Lobbying Issues
Education about the value of innovative new medicines and the Orphan Drug Act.
H.R.1231/S.456: RACE for Children Act.
H.R.2430/S.934: FDA Reauthorization Act of 2017.
Education about the 340(b)m program.
H.R.3472: Access to Marketplace Insurance Act.
S. 204: Trickett Wendler Right to Try Act of 2017.
H.R. 1628: American Health Care Act. Better Care Reconciliation Act.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2017
In Q1, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $60,000. The report was filed on April 21, 2017.
Original Filing: 300878592.xml
Lobbying Issues
Education about the value of innovative new medicines and the Orphan Drug Act.
H.R. 749: Lower Drug Prices Through Competition Act.
S. 204: Trickett Wendler Right to Try Act of 2017.
H.R. 1628: American Health Care Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Educated staff about access to therapies for rare diseases in Medicaid.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2016
In Q4, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $50,000. The report was filed on Jan. 18, 2017.
Original Filing: 300848343.xml
Lobbying Issues
Education about the value of innovative new medicines.
H.R. 34: 21st Century Cures Act as it relates to S. 1878: To extend the pediatric priority review voucher program.
S. 3056: CREATES Act of 2016.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Educated staff about access to therapies for rare diseases in Medicaid.
March 2016 CMS proposed rule implementing a new Part B drug payment model.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2016
In Q3, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $50,000. The report was filed on Oct. 20, 2016.
Original Filing: 300834935.xml
Lobbying Issues
Education about the value of innovative new medicines.
S. 1878: "To extend the pediatric priority review voucher program".
S. 3056: CREATES Act of 2016.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Educated staff about access to therapies for rare diseases in Medicaid.
Education about reimbursement for orphan drug therapies in skilled nursing facilities and proposed add-on payments in inpatient hospitals.
March 2016 CMS proposed rule implementing a new Part B drug payment model.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2016
In Q2, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $50,000. The report was filed on July 19, 2016.
Original Filing: 300815094.xml
Lobbying Issues
Education about the value of innovative new medicines.
S. 1878: "To extend the pediatric priority review voucher program".
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Educated staff about access to therapies for rare diseases in Medicaid.
Education about reimbursement for orphan drug therapies in skilled nursing facilities and proposed add-on payments in inpatient hospitals.
March 2016 CMS proposed rule implementing a new Part B drug payment model.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Trans Pacific Partnership agreement with respect to data exclusivity for biologics.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2016
In Q1, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $50,000. The report was filed on April 20, 2016.
Original Filing: 300803036.xml
Lobbying Issues
Education about the value of innovative new medicines.
S. 1878: "To extend the pediatric priority review voucher program".
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Educated staff about access to therapies for rare diseases.
Education about reimbursement for orphan drug therapies in skilled nursing facilities and proposed add-on payments in inpatient hospitals.
March 2016 CMS proposed rule implementing a new Part B drug payment model.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Trans Pacific Partnership agreement with respect to data exclusivity for biologics.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2015
In Q4, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $50,000. The report was filed on Jan. 20, 2016.
Original Filing: 300783977.xml
Lobbying Issues
Education about the value of innovative new medicines.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Educated staff about access to therapies for rare diseases.
Education about reimbursement for orphan drug therapies in skilled nursing facilities and proposed add-on payments in inpatient hospitals.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Trans Pacific Partnership agreement with respect to data exclusivity for biologics.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2015
In Q3, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $50,000. The report was filed on Oct. 20, 2015.
Original Filing: 300763538.xml
Lobbying Issues
Implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars.
H.R. 6: 21st Century Cures Act.
Education about the value of innovative new medicines.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Educated staff about access to therapies for rare diseases.
Education about reimbursement for orphan drug therapies in skilled nursing facilities and proposed add-on payments in inpatient hospitals.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1314: Trade Preferences Extension Act as it relates to access to orphan drug therapies.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.R. 9: Innovation Act, including proposed changes to the Inter Partes Review (IPR) process at the Patent and Trademark Office (PTO).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2015
In Q2, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $50,000. The report was filed on July 20, 2015.
Original Filing: 300743439.xml
Lobbying Issues
Implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars.
H.R. 6: 21st Century Cures Act.
Education about the value of innovative new medicines.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Educated staff about access to therapies for rare diseases.
Education about reimbursement for orphan drug therapies in skilled nursing facilities and proposed add-on payments in inpatient hospitals.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1314: Trade Preferences Extension Act as it relates to access to orphan drug therapies.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.R. 9: Innovation Act, including proposed changes to the Inter Partes Review (IPR) process at the Patent and Trademark Office (PTO).
S. 1137: PATENT Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2015
In Q1, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $50,000. The report was filed on April 17, 2015.
Original Filing: 300718810.xml
Lobbying Issues
Implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars.
Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).
Education about the value of innovative new medicines.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Educated staff about access to therapies for rare diseases.
Education about reimbursement for orphan drug therapies in skilled nursing facilities.
H.R. 2: Medicare Access and CHIP Reauthorization Act of 2015.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislative efforts to provide trade promotion authority as it relates to access to orphan drug therapies.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2014
In Q4, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $50,000. The report was filed on Jan. 19, 2015.
Original Filing: 300700295.xml
Lobbying Issues
Implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars.
Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).
Education about the value of innovative new medicines.H.R. 1281: Newborn Screening Saves Lives Reauthorization Act of 2014.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Educated staff about access to therapies for rare diseases.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2014
In Q3, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $50,000. The report was filed on Oct. 16, 2014.
Original Filing: 300684677.xml
Lobbying Issues
Implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars.
Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).
Education about the value of innovative new medicines.H.R. 5657: Fair Access for Safe and Timely Generics Act of 2014.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2014
In Q2, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $50,000. The report was filed on July 14, 2014.
Original Filing: 300664780.xml
Lobbying Issues
Implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars.
Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).
Education about the value of innovative new medicines.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2014
In Q1, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $50,000. The report was filed on April 14, 2014.
Original Filing: 300635666.xml
Lobbying Issues
Implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 4302: Protecting Access to Medicare Act of 2014.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 1720: Patent Transparency and Improvements Act.
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2013
In Q4, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $50,000. The report was filed on Jan. 14, 2014.
Original Filing: 300621909.xml
Lobbying Issues
Monitored implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1416: Cancer Patient Protection Act of 2013.
H.R. 2810, S: Medicare Patient Access and Quality Improvement Act of 2013.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2013
In Q3, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $50,000. The report was filed on Oct. 16, 2013.
Original Filing: 300601801.xml
Lobbying Issues
H.R. 1919: Safeguarding Americas Pharmaceuticals Act of 2013.
S. 957: Drug Supply Chain Security Act.
S. 959: Pharmaceutical Compounding Quality and Accountability Act.
H.R. 3089: Compounding Clarity Act of 2013.H.R. 3024: The Drug Quality and Security Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education with respect to the transparency of biopharmaceutical pricing in France.
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.R. 1416: Cancer Patient Protection Act of 2013.
Monitored legislative efforts to reform the Sustainable Growth Rate (SGR) formula for physicians in Medicare.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2013
In Q2, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $50,000. The report was filed on July 15, 2013.
Original Filing: 300577089.xml
Lobbying Issues
H.R. 1919: Safeguarding Americas Pharmaceuticals Act of 2013.
S. 957: Drug Supply Chain Security Act.
S. 959: Pharmaceutical Compounding Quality and Accountability Act.Education about the Pre-Existing Condition Insurance Plan (PCIP) in the Affordable Care Act and legislative efforts to redirect funding from other sources into the program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitoring the implementation of the Korea-U.S. Free Trade Agreement, as it relates to transparency in Korean government coverage and reimbursement of biologics.
Education about transparency of drug pricing and reimbursement in France.
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.R. 1416: Cancer Patient Protection Act of 2013.
Monitored legislative efforts to reform the Sustainable Growth Rate (SGR) formula for physicians in Medicare.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2013
In Q1, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $50,000. The report was filed on April 16, 2013.
Original Filing: 300553116.xml
Lobbying Issues
Federal legislative efforts to enhance the security and integrity of the domestic pharmaceutical distribution system.
Education about the Pre-Existing Condition Insurance Plan (PCIP) in the Affordable Care Act and legislative efforts to redirect funding from other sources into the program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitoring the implementation of the Korea-U.S. Free Trade Agreement, as it relates to transparency in Korean government coverage and reimbursement of biologics.
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.R. 8: American Taxpayer Relief Act of 2012 as it relates to sequestration and Medicare, including updates to the Medicare Sustainable Growth rate formula for physicians and related issues.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2012
In Q4, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $50,000. The report was filed on Jan. 14, 2013.
Original Filing: 300536605.xml
Lobbying Issues
Federal legislative efforts to enhance the security and integrity of the domestic pharmaceutical distribution system.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitoring the implementation of the Korea-U.S. Free Trade Agreement, as it relates to transparency in Korean government coverage and reimbursement of biologics.
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.R. 8: American Taxpayer Relief Act of 2012 as it relates to sequestration and Medicare, including updates to the Medicare Sustainable Growth rate formula for physicians and related issues.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $50,000. The report was filed on Oct. 10, 2012.
Original Filing: 300512135.xml
Lobbying Issues
Federal legislative efforts to enhance the security and integrity of the domestic pharmaceutical distribution system.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitoring the implementation of the Korea-U.S. Free Trade Agreement, as it relates to transparency in Korean government coverage and reimbursement of biologics.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2012
In Q2, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $50,000. The report was filed on July 19, 2012.
Original Filing: 300494014.xml
Lobbying Issues
S. 2236: Advancing Breakthrough Therapies for Patients Act.
H.R. 5651: Food and Drug Administration Reform Act of 2012.
S. 3187: Food and Drug Administration Safety and Innovation Act of 2012.
H.R. 4132: Faster Access to Specialized Treatments Act.Federal legislative efforts to enhance the security and integrity of the domestic pharmaceutical distribution system.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitoring the implementation of the Korea-U.S. Free Trade Agreement, as it relates to transparency in Korean government coverage and reimbursement of biologics.
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2012
In Q1, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $50,000. The report was filed on April 18, 2012.
Original Filing: 300463993.xml
Lobbying Issues
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to regulatory pathway for biosimilars and orphan drugs and opposing efforts in the President's Budget to alter that pathway.
S. 2236: Advancing Breakthrough Therapies for Patients Act.
Development of reauthorizing legislation implementing the Prescription Drug User Fee Act (PDUFA) and related issues.H.R. 4132: Faster Access to Specialized Treatments Act.
Federal legislative efforts to enhance the security and integrity of the domestic pharmaceutical distribution system.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitored H.R. 3630: Temporary Payroll Tax Cut Continuation Act of 2011 as it relates to Medicare reimbursement for Part B drugs.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2011
In Q4, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $50,000. The report was filed on Jan. 19, 2012.
Original Filing: 300445536.xml
Lobbying Issues
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to regulatory pathway for biosimilars and orphan drugs.
Lobbying Issues
H.R. 3630/H.R. 3765: Temporary Payroll Tax Cut Continuation Act of 2011 as they related to Medicare reimbursement for Part B drugs.
P.L. 112-25 - The Budget Control Act of 2011 as it relates to Medicare reimbursement for Part B drugs.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education and outreach to Congressional staff on coverage and reimbursement of drugs in the Republic of Korea.
P.L. 112-41, The United States-Korea Free Trade Agreement Implementation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2011
In Q3, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $50,000. The report was filed on Oct. 20, 2011.
Original Filing: 300423936.xml
Lobbying Issues
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to regulatory pathway for biosimilars and orphan drugs.
Education and outreach on treatment of rare diseases to Congressional staff.
Monitored deficit reduction initiatives related to enactment of an increase in the U.S. federal debt ceiling. P.L. 112-25 - The Budget Control Act of 2011 as it relates to proposals affecting reimbursement of Part B drugs.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
P.L. 112-25 - The Budget Control Act of 2011 as it relates to Medicare reimbursement for Part B drugs.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2011
In Q2, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $50,000. The report was filed on July 19, 2011.
Original Filing: 300395805.xml
Lobbying Issues
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to regulatory pathway for biosimilars and orphan drugs.
Education and outreach on treatment of rare diseases to Congressional staff.
Monitored deficit reduction initiatives related to enactment of an increase in the U.S. federal debt ceiling.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Educated about reimbursement issues in Korea.
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Patent Reform
H.R. 1249 - America Invents Act of 2011
Agencies Lobbied
U.S. House of Representatives,
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2011
In Q1, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $50,000. The report was filed on April 16, 2011.
Original Filing: 300369403.xml
Lobbying Issues
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to regulatory pathway for biosimilars and orphan drugs and annual and lifetime coverage limits.
Education and outreach on treatment of rare diseases to Congressional staff.
H.R. 2 - Repealing the Job-Killing Health Care Law Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Educated about reimbursement issues in Korea.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Patent Reform
S.23 - America Invents Act of 2011
H.R. 1249 - America Invents Act of 2011
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2010
In Q4, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $50,000. The report was filed on Jan. 12, 2011.
Original Filing: 300346581.xml
Lobbying Issues
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to regulatory pathway for biosimilars and orphan drugs.
Education and outreach on treatment of rare diseases to Congressional staff.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2010
In Q3, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $50,000. The report was filed on Oct. 15, 2010.
Original Filing: 300321243.xml
Lobbying Issues
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to regulatory pathway for biosimilars and orphan drugs.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2010
In Q2, W Strategies, LLC lobbied for Alexion Pharmaceuticals , earning $30,000. The report was filed on July 20, 2010.
Original Filing: 300297983.xml
Lobbying Issues
Advise client on implementation of the Patient Protection and Affordable Care Act, specifically with respect to the creation of a regulatory pathway for biosimilars and provisions dealing with insurance limits (annual/lifetime).
Advise client on legislation related to the 340(b) Drug Pricing Program as it relates to orphan drugs.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitor legislation related to patent reform.
S. 515 - Patent Reform Act
H.R. 1260 - Patent Reform Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2010
W Strategies, LLC filed a lobbying registration on June 13, 2010 to represent Alexion Pharmaceuticals, effective May 1, 2010.
Original Filing: 300280517.xml
Issue(s) they said they’d lobby about: Advise client on implementation of the Patient Protection and Affordable Care Act and monitor legislation related to patent reform .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...